Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
JAMA
    September 2026
  1. SHANMUGAM H, Kesselheim AS, McGuire M, Rome BN, et al
    Prescription Drug Launch Price Trends Before and After the Inflation Reduction Act.
    JAMA. 2026 Sep 30:e2617742. doi: 10.1001/jama.2026.17742.
    >> Share

    July 2026
  2. WOODS J, Lebina L, Moller K, Venter WDF, et al
    Initial HIV Therapy for Adults and Treatment-Associated Weight Gain: The Opti-DOR Randomized Clinical Trial.
    JAMA. 2026 Jul 31. doi: 10.1001/jama.2026.14762.
    >> Share

  3. HWANG TJ, Clemans-Cope L, Kesselheim AS
    Savings Under Most-Favored-Nation Pricing for Prescription Drugs in Medicaid.
    JAMA. 2026 Jul 15:e269973. doi: 10.1001/jama.2026.9973.
    >> Share

    May 2026
  4. JENG WJ, Yip TC, Lok AS
    Hepatitis B: A Review.
    JAMA. 2026 May 4. doi: 10.1001/jama.2026.6070.
    >> Share

    November 2025
  5. MAUERMANN ML, Staff NP
    Peripheral Neuropathy: A Review.
    JAMA. 2025 Nov 17. doi: 10.1001/jama.2025.19400.
    >> Share

    July 2025
  6. MAFI JN, Vangala S, Kahn KL
    Nirmatrelvir-Ritonavir Access and Hospitalizations and Mortality in Older Adults-Reply.
    JAMA. 2025 Jul 2. doi: 10.1001/jama.2025.6491.
    >> Share

  7. HAO W
    Nirmatrelvir-Ritonavir Access and Hospitalizations and Mortality in Older Adults.
    JAMA. 2025 Jul 2. doi: 10.1001/jama.2025.6488.
    >> Share

    April 2025
  8. PAN CQ, Yang C, Dai E
    Tenofovir and Hepatitis B Transmission During Pregnancy-Reply.
    JAMA. 2025 Apr 29. doi: 10.1001/jama.2025.1943.
    >> Share

  9. YU L
    Tenofovir and Hepatitis B Transmission During Pregnancy.
    JAMA. 2025 Apr 29. doi: 10.1001/jama.2025.1940.
    >> Share

    February 2025
  10. MAFI JN, Vangala S, Kapral MK, Wu PE, et al
    Hospitalizations and Mortality Among Older Adults With and Without Restricted Access to Nirmatrelvir-Ritonavir.
    JAMA. 2025 Feb 20. doi: 10.1001/jama.2024.28099.
    >> Share

    November 2024
  11. MARTIN MJ, Gabriele SME, Kesselheim AS, Tu SS, et al
    Characteristics of Academic Inventors on Government-Linked US Drug Patents.
    JAMA. 2024 Nov 21:e2420361. doi: 10.1001/jama.2024.20361.
    >> Share

  12. PAN CQ, Dai E, Mo Z, Zhang H, et al
    Tenofovir and Hepatitis B Virus Transmission During Pregnancy: A Randomized Clinical Trial.
    JAMA. 2024 Nov 14. doi: 10.1001/jama.2024.22952.
    >> Share

    September 2024
  13. RUBIN R
    The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits.
    JAMA. 2024 Sep 6. doi: 10.1001/jama.2024.16432.
    >> Share

    August 2024
  14. TU SS, Kesselheim AS, Chao B
    Extent of Drug Patents With Terminal Disclaimers and Obviousness-Type Double Patenting Rejections.
    JAMA. 2024 Aug 12:e2414350. doi: 10.1001/jama.2024.14350.
    >> Share

    March 2024
  15. SHETH AN, Momplaisir F, Dumond JB
    Shifting the Narrative of Preexposure Prophylaxis Adherence Counseling for Cisgender Women.
    JAMA. 2024;331:912-914.
    >> Share

  16. MARRAZZO J, Tao L, Becker M, Leech AA, et al
    HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women.
    JAMA. 2024 Mar 1. doi: 10.1001/jama.2024.0464.
    >> Share

    February 2024
  17. SARPATWARI A, Kohli S, Tu SS, Kesselheim AS, et al
    Patents on Risk Evaluation and Mitigation Strategies for Prescription Drugs and Generic Competition.
    JAMA. 2024 Feb 22:e240924. doi: 10.1001/jama.2024.0924.
    >> Share

  18. ALHIARY R, Gabriele S, Kesselheim AS, Tu SS, et al
    Delivery Device Patents on GLP-1 Receptor Agonists.
    JAMA. 2024 Feb 5:e240919. doi: 10.1001/jama.2024.0919.
    >> Share

    January 2024
  19. RUBIN R
    Paxlovid Is Effective but Underused-Here's What the Latest Research Says About Rebound and More.
    JAMA. 2024 Jan 31. doi: 10.1001/jama.2023.28254.
    >> Share

    December 2023
  20. SURAN M
    Studies Investigate Whether Antivirals Like Paxlovid May Prevent Long COVID.
    JAMA. 2023 Dec 13. doi: 10.1001/jama.2023.24103.
    >> Share

    November 2023
  21. TU SS, Leadmon C, Daval CJR, Kesselheim AS, et al
    Inequitable Conduct and Invalidation of Patents Related to Food and Drug Administration-Regulated Products.
    JAMA. 2023 Nov 13:e2320196. doi: 10.1001/jama.2023.20196.
    >> Share

  22. NEGRO F, Lok AS
    Hepatitis D: A Review.
    JAMA. 2023 Nov 9. doi: 10.1001/jama.2023.23242.
    >> Share

    August 2023
  23. CHOU R, Spencer H, Bougatsos C, Blazina I, et al
    Preexposure Prophylaxis for the Prevention of HIV: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2023;330:746-763.
    >> Share

  24. RAGLOW Z, Malani PN, Petty LA
    Outpatient Treatment for COVID-19.
    JAMA. 2023 Aug 16. doi: 10.1001/jama.2023.16666.
    >> Share

  25. TU SS, Kesselheim AS, Wetherbee K, Feldman WB, et al
    Changes in the Number of Continuation Patents on Drugs Approved by the FDA.
    JAMA. 2023;330:469-470.
    >> Share

    June 2023
  26. HARRIS E
    FDA Grants Full Approval to Paxlovid, COVID-19 Antiviral Treatment.
    JAMA. 2023 Jun 7. doi: 10.1001/jama.2023.9925.
    >> Share

    April 2023
  27. EGILMAN AC, Rome BN, Kesselheim AS
    Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare.
    JAMA. 2023;329:1283-1289.
    >> Share

    February 2023
  28. HARRIS E
    Paxlovid Alternative Is Similarly Effective.
    JAMA. 2023;329:622-623.
    >> Share

    December 2022
  29. SURAN M
    VA Finds Nirmatrelvir Associated With Lower Risk of Long COVID.
    JAMA. 2022;328:2386.
    >> Share

  30. HIGGINS AM, Berry LR, Lorenzi E, Murthy S, et al
    Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
    JAMA. 2022 Dec 16. doi: 10.1001/jama.2022.23257.
    >> Share

  31. KUEHN BM
    Inequity in Paxlovid Prescribing.
    JAMA. 2022;328:2203-2204.
    >> Share

  32. GANDHI RT, Bedimo R, Hoy JF, Landovitz RJ, et al
    Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.
    JAMA. 2022 Dec 1. doi: 10.1001/jama.2022.22246.
    >> Share

    October 2022
  33. LARKIN HD
    Paxlovid Drug Interaction Screening Checklist Updated.
    JAMA. 2022;328:1290.
    >> Share

    September 2022
  34. LARKIN HD
    Paxlovid Expiration Dates Extended.
    JAMA. 2022;328:819.
    >> Share

    July 2022
  35. KUEHN BM
    Rehospitalization, Emergency Visits After Paxlovid Treatment Are Rare.
    JAMA. 2022;328:323.
    >> Share

    June 2022
  36. RUBIN R
    From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid.
    JAMA. 2022 Jun 8. pii: 2793357. doi: 10.1001/jama.2022.9925.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016